MHRA Approved June 2026 Novo Nordisk Wegovy Tablets Once-daily oral semaglutide tablets the weight loss tablet that's changing everything Once-daily oral semaglutide tablet same active ingredient as the Wegovy injection, now in tablet form Clinically proven participants lost up to 16.6% of body weight after 64 weeks (OASIS 4 trial) Available in four tablet strengths: 1.5mg, 4mg, 9mg, and 25mg No needles, no sharps bin, no refrigeration required Made by Novo Nordisk the manufacturer of Wegovy injections and Ozempic MHRA-approved on 11 June 2026 available from 7th July 2026 Prescription-only medicine
They assess whether you are a candidate for semaglutide therapy and discuss the treatment plan
Morsy, M
Oral Medication: You can take glutathione pills by mouth, but they might not work as well because of problems with the stomach and absorption
Phase 2 trial data published in the New England Journal of Medicine showed an average of 24.2% body weight reduction at the highest research quantities over 48 weeks
The purpose of this gradual increase is to: Reduce gastrointestinal side effects Allow the body to adapt to GLP-1 activity Improve long-term adherence to treatment Maximize fat loss results safely Patients who follow the correct dosing schedule are significantly more likely to achieve sustainable weight loss results compared to those who skip steps or increase dosage too quickly